Get the Stockscreener App
2.85
0.00%
0.00
Pre-market:
2.57
-0.28
-9.82%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.85, with a volume of 503.75K.
It is up +0.00% in the last 24 hours and up +2.15% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.85
Open:
$2.9
24h Volume:
503.75K
Relative Volume:
0.19
Market Cap:
$137.68M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-2.0652
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-9.52%
1M Performance:
+2.15%
6M Performance:
+37.68%
1Y Performance:
+18.26%
1-Day Range:
$2.84
$2.97
1-Week Range:
$2.7718
$3.20
52-Week Range:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.85 | 137.68M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Why Cassava Sciences Inc. Equity Warrant stock remains undervaluedPortfolio Performance Report & Weekly Return Optimization Plans - Улправда
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy By Investing.com - Investing.com South Africa
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy - Investing.com
Cassava Sciences Receives FDA Clinical Hold on Simufilam Trial - TradingView — Track All Markets
Published on: 2025-12-18 21:27:30 - Улправда
How Cassava Sciences Inc. stock responds to policy changes2025 Sector Review & Reliable Price Breakout Signals - Улправда
Cassava Sciences (SAVA) Stock Analysis Report | Financials & Insights - Benzinga
Cassava Sciences Submits IND Application for Simufilam - MSN
Is Pressure Sensitive Systems India Limited Stock a Safe LongTerm Investment Data BreakdownUtilities Sector Analysis & Let Our AI Be Your Trading Assistant - earlytimes.in
Cassava Sciences rises 10% after market close on CEO stock buy - MSN
Why Cassava Sciences Inc. Equity Warrant stock is rated strong buyDividend Hike & High Accuracy Investment Signals - Newser
Why Cassava Sciences Inc. (PX91) stock appeals to dividend investors2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Why Cassava Sciences Inc. (PX91) stock could be next leader2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Can Cassava Sciences Inc. (PX91) stock deliver double digit returnsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
How Cassava Sciences Inc. Equity Warrant stock compares to industry benchmarksPortfolio Value Summary & AI Forecasted Entry and Exit Points - Newser
How Cassava Sciences Inc. (PX91) stock trades after rate cuts2025 Performance Recap & AI Powered Buy/Sell Recommendations - Newser
Cassava Sciences Shares Drop as FDA Seeks Additional Data for Epilepsy Program - MSN
Cassava Sciences IncFDA requires additional information from Cassava for clinical studySEC filing - marketscreener.com
Cassava Says US FDA Seeks Additional Information for Simufilam IND Application for TSC-Related Epilepsy - marketscreener.com
Cassava Sciences hit with FDA request for more data on simufilam trial (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences receives FDA request for more information on epilepsy trial - Investing.com
Cassava Sciences stock falls after FDA requests more data for epilepsy drug - Investing.com Canada
Does Cassava Sciences Inc. stock trade at a discount to peersAnalyst Downgrade & Weekly High Return Stock Forecasts - Newser
Cassava Sciences Receives FDA Request for Additional Information - TradingView — Track All Markets
Will Cassava Sciences Inc. (PX91) stock beat Nasdaq index returnsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Is Cassava Sciences Inc. stock a buy for dividend growthJuly 2025 Market Mood & Low Risk Investment Opportunities - Newser
Published on: 2025-12-02 02:52:36 - Newser
Can Cassava Sciences Inc. stock outperform in 2025 bull marketWeekly Trade Report & Free Weekly Watchlist of Top Performers - moha.gov.vn
November 2025's Top Penny Stock Opportunities - Yahoo Finance
Aug Sectors: What valuation multiples suggest for Cassava Sciences Inc. Equity Warrant stockDollar Strength & Real-Time Sentiment Analysis - BỘ NỘI VỤ
Dir Anderson Jr Buys 8,600 ($24.9K) Of Cassava Sciences Inc [SAVA] - TradingView
[Form 4] CASSAVA SCIENCES INC Insider Trading Activity - Stock Titan
Cassava Pops After CEO Buys 150,000 Shares - Yahoo Finance
CEO Makes Bold Investment in Cassava Sciences - TipRanks
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Cla - GuruFocus
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - MSN
Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock - MarketBeat
Should You Invest in Dishman Carbogen Amcis Limited Before Its Next Earnings ReportEvening Star Patterns & Rapid Capital Portfolio - earlytimes.in
Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA) - MarketBeat
Cassava Sciences Stock Rise as CEO Makes Insider Purchase - Somos Hermanos -
Is Cassava Sciences Inc. stock attractive for retirement portfoliosGap Up & Safe Capital Allocation Plans - newser.com
Cassava Sciences stock up as CEO buys shares (SAVA:NASDAQ) - Seeking Alpha
Is Cassava Sciences Inc. stock attractive for income investorsMarket Trend Report & AI Enhanced Trading Signals - newser.com
Is Cassava Sciences Inc. stock a defensive play in 2025Market Performance Report & AI Powered Market Entry Strategies - newser.com
Why global investors buy Cassava Sciences Inc. (PX91) stockPortfolio Value Summary & Low Risk High Reward Trade Ideas - newser.com
Why Cassava Sciences Inc. Equity Warrant stock could be next big winnerPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Can Cassava Sciences Inc. stock deliver consistent earnings growth2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):